Mike Hollan is an assistant managing editor for Pharmaceutical Executive and Medical Device and Technology and can be reached at mhollan@mjhlifesciences.com.
DE&I in Pharma: A Shared Aim Promoting Inclusivity from Non-Leadership Roles
July 10th 2023In today's changing workplace environment—one forever altered by the pandemic and the new approaches it spawned—employees at all levels play a vital role in developing and advancing inclusive behaviors across an organization and beyond.
A New Era of Influence: Embracing the KOL-DOL Dynamic in Healthcare
March 10th 2023How pharma companies can leverage the lessons learned during the pandemic around key opinion leaders and digital opinion leaders, respectively, to best use new channels of communication. Can both coexist across the healthcare engagement spectrum?
Focus and Fundamentals: CFO Strategies on the Journey to Commercialization
February 9th 2023Chief financial officers and other finance experts discuss the continued market volatility impacting life sciences investment—and what biopharma companies can do to help accelerate its recovery. Quality science and “good data” still win the day.
Stars Aligned for Pricing Model? Value-Based Contracts May be Poised for Takeoff
January 11th 2023As new forms of cell and gene therapies continue to be developed, life sciences companies and payers need to find alternative ways to pay for these expensive treatments. Value-based contracts, though slow to gain traction so far, may provide the solution these groups are looking for.
Whole-Person Care: Are We Ready? The Intersection of Pharma and Digital Therapeutics
November 8th 2022Senior leaders focused on the advancement of digital medicine and health meet to discuss the importance of these tools for life sciences companies, payers, and others in harnessing a healthcare future that will be increasingly dominated by holistic treatment and delivery.
Assessing HCP-Visit Fallout: COVID’s Ultimate Impact on New Drug Entrants
September 9th 2022Tracking the pandemic’s influence on brand awareness and prescribing efforts in light of decline in physician visits and fewer diagnoses—and what these dynamics, still unsettled post-pandemic, might mean for future launches.